JOP20190129A1 - تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين - Google Patents

تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين

Info

Publication number
JOP20190129A1
JOP20190129A1 JOP/2019/0129A JOP20190129A JOP20190129A1 JO P20190129 A1 JOP20190129 A1 JO P20190129A1 JO P20190129 A JOP20190129 A JO P20190129A JO P20190129 A1 JOP20190129 A1 JO P20190129A1
Authority
JO
Jordan
Prior art keywords
piperidine
ht1f
pyridinoyl
adjuvants
combinations
Prior art date
Application number
JOP/2019/0129A
Other languages
English (en)
Inventor
Brigida Allieri
Paul Fagan
Raymond D Skwierczynski
Emma Sharp
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20190129(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of JOP20190129A1 publication Critical patent/JOP20190129A1/ar
Application granted granted Critical
Publication of JOP20190129B1 publication Critical patent/JOP20190129B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يوفر الاختراع الحالي أشكال متعددة زائفة جديدة من ملح هيمي سكسينات من 2، 4، 6-تراي فلورو-N-[6-(1-ميثيل-بيبريدين-4-كربونيل)-بيريدين-2-يل]-بنزاميد مفيدة في التركيبات الصيدلية، على سبيل المثال، لعلاج والوقاية من الصداع النصفي.
JOP/2019/0129A 2016-12-06 2017-12-05 تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين JOP20190129B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662430662P 2016-12-06 2016-12-06
PCT/US2017/064652 WO2018106657A1 (en) 2016-12-06 2017-12-05 Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists

Publications (2)

Publication Number Publication Date
JOP20190129A1 true JOP20190129A1 (ar) 2019-05-29
JOP20190129B1 JOP20190129B1 (ar) 2023-03-28

Family

ID=60972336

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0129A JOP20190129B1 (ar) 2016-12-06 2017-12-05 تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين

Country Status (38)

Country Link
US (1) US11053214B2 (ar)
EP (1) EP3551617B1 (ar)
JP (4) JP2020500936A (ar)
KR (4) KR20230008257A (ar)
CN (3) CN115385894A (ar)
AU (1) AU2017373784B2 (ar)
BR (1) BR112019010934A2 (ar)
CA (1) CA3043772C (ar)
CL (1) CL2019001426A1 (ar)
CO (1) CO2019005290A2 (ar)
CR (1) CR20190251A (ar)
CY (1) CY1124540T1 (ar)
DK (1) DK3551617T3 (ar)
DO (1) DOP2019000139A (ar)
EA (1) EA201991112A1 (ar)
EC (1) ECSP19040190A (ar)
ES (1) ES2889476T3 (ar)
HR (1) HRP20211557T1 (ar)
HU (1) HUE056820T2 (ar)
IL (1) IL266598B2 (ar)
JO (1) JOP20190129B1 (ar)
LT (1) LT3551617T (ar)
MA (1) MA52920B1 (ar)
MD (1) MD3551617T2 (ar)
MX (2) MX392547B (ar)
MY (1) MY196855A (ar)
NZ (1) NZ752906A (ar)
PE (2) PE20191134A1 (ar)
PH (1) PH12019501252B1 (ar)
PL (1) PL3551617T3 (ar)
PT (1) PT3551617T (ar)
RS (1) RS62415B1 (ar)
SI (1) SI3551617T1 (ar)
TN (1) TN2019000174A1 (ar)
TW (1) TWI671290B (ar)
UA (1) UA124433C2 (ar)
WO (1) WO2018106657A1 (ar)
ZA (1) ZA201903449B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753171A (zh) 2009-04-02 2012-10-24 科鲁西德制药公司 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI829107B (zh) * 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN111004214B (zh) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
US12271057B1 (en) 2019-12-20 2025-04-08 The Uab Research Foundation Chromatic aberration tuning ophthalmic corrector lens methods
WO2022236004A1 (en) 2021-05-07 2022-11-10 Eli Lilly And Company Taste masked compostions of 2,4,6-trifluoro- n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2- ylj-benzamide hemisuccinate, and orally disentegrating tablet comprising the same
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
CN102753171A (zh) 2009-04-02 2012-10-24 科鲁西德制药公司 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US20140221385A1 (en) 2011-06-01 2014-08-07 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
US10669256B2 (en) 2016-07-15 2020-06-02 Hangzhou Solipharma Co., Ltd. Crystalline forms of lasmiditan, preparation methods, pharmaceutical compositions and uses thereof
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
IL266598B2 (en) 2024-05-01
PH12019501252B1 (en) 2024-05-24
AU2017373784B2 (en) 2020-04-23
MA52920A (fr) 2021-04-28
KR20190075130A (ko) 2019-06-28
TN2019000174A1 (en) 2020-10-05
DK3551617T3 (da) 2021-09-13
CO2019005290A2 (es) 2019-05-31
IL266598B1 (en) 2024-01-01
KR20230008257A (ko) 2023-01-13
DOP2019000139A (es) 2019-08-15
IL266598A (en) 2019-07-31
JOP20190129B1 (ar) 2023-03-28
US11053214B2 (en) 2021-07-06
SI3551617T1 (sl) 2021-11-30
MD3551617T2 (ro) 2021-12-31
ES2889476T3 (es) 2022-01-12
KR20250070124A (ko) 2025-05-20
CA3043772C (en) 2022-06-07
PH12019501252A1 (en) 2019-12-02
WO2018106657A1 (en) 2018-06-14
PT3551617T (pt) 2021-10-04
PE20241297A1 (es) 2024-06-24
US20200087279A1 (en) 2020-03-19
ZA201903449B (en) 2021-02-24
EA201991112A1 (ru) 2019-10-31
CL2019001426A1 (es) 2019-10-11
AU2017373784A1 (en) 2019-05-16
HRP20211557T1 (hr) 2022-01-07
PE20191134A1 (es) 2019-09-02
JP2022000451A (ja) 2022-01-04
PL3551617T3 (pl) 2021-12-20
JP2023123678A (ja) 2023-09-05
MX388091B (es) 2025-03-19
NZ752906A (en) 2021-07-30
CN115385893A (zh) 2022-11-25
MX2021014139A (es) 2022-05-24
UA124433C2 (uk) 2021-09-15
CR20190251A (es) 2019-08-26
BR112019010934A2 (pt) 2019-10-01
CY1124540T1 (el) 2022-07-22
TW201833097A (zh) 2018-09-16
JP2020500936A (ja) 2020-01-16
LT3551617T (lt) 2021-10-11
CN110291079A (zh) 2019-09-27
TWI671290B (zh) 2019-09-11
JP7561240B2 (ja) 2024-10-03
JP7818666B2 (ja) 2026-02-20
CA3043772A1 (en) 2018-06-14
MX392547B (es) 2025-03-24
MY196855A (en) 2023-05-05
EP3551617B1 (en) 2021-08-11
HUE056820T2 (hu) 2022-03-28
RS62415B1 (sr) 2021-10-29
CN115385894A (zh) 2022-11-25
ECSP19040190A (es) 2019-08-30
KR20210102497A (ko) 2021-08-19
EP3551617A1 (en) 2019-10-16
MA52920B1 (fr) 2021-11-30
JP2024178323A (ja) 2024-12-24
MX2019006520A (es) 2019-08-21

Similar Documents

Publication Publication Date Title
JOP20190129A1 (ar) تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين
PH12018501226A1 (en) Methods for treating huntingtons disease
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201790271A1 (ru) Ингибиторы гликозидазы
MX2018013983A (es) Inhibidores g12c de kras.
JO3474B1 (ar) مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
MY199220A (en) Heterocyclic compounds as immunomodulators
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA033163B1 (ru) Ингибиторы глутаминазы
EA201891644A1 (ru) Антибактериальные соединения и их применение
GEAP201814485A (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
CY1123892T1 (el) Κρυσταλλικες μορφες του 6-((6,7-διμεθοξυκιναζολιν-4-υλο)οξυ)-ν,2-διμεθυλοβενζοφουρανο-3-καρβοξαμιδιου
JOP20170102B1 (ar) أشكال بلورية منn- [2-(3-هيدروكسي-3-مثيل بيوتيل)-6-(2-هيدروكسي بروبان-2-يل)-2h-إندازول-5-يل]-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
CY1120700T1 (el) Ενωσεις τριαμινοπυριμιδινης χρησιμες για προληψη ή αγωγη ελονοσιας
EA201891342A1 (ru) Изоиндольные соединения
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
GEAP202115141A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
JOP20190045A1 (ar) مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2019005294A (es) Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.